Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Eli Lilly launches once-daily weight-loss pill Foundayo

The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy

REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia